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1. Introduction 
Amyloids are insoluble fibrous protein aggregates sharing specific structural traits. 
Abnormal accumulation of amyloid in organs may lead to amyloidosis, and may play a role 
in various diseases. The name amyloid comes from the early mistaken identification of the 
substance as starch (amylum in Latin), based on crude iodine-staining techniques. For a 
period, it was debated whether or not amyloid deposits were fatty or carbohydrate deposits 
until it was finally found that they were, in fact, deposits of proteinaceous mass. The 
underlying molecular abnormalities may be either acquired or hereditary and more than 20 
different proteins can form clinically or pathologically significant amyloid fibrils in vivo. 
Current nomenclature lists of amyloid fibril protein have been provided from the 
nomenclature committee of the International Society of Amyloidosis. 
Amyloidosis is a disorder of protein conformation and metabolism that results in the 
deposition of insoluble amyloid fibrils in tissues, which causes organ dysfunction; systemic 
amyloidosis is characterized by failure of various organs and the presence of amyloid 
precursor protein in the serum. Reactive amyloid A (AA) amyloidosis is one of the most 
severe complications of several chronic disorders, particularly rheumatoid arthritis (RA), 
and indeed, most patients with reactive AA amyloidosis have an underlying rheumatic 
disease. An extra-articular complication of RA, AA amyloidosis is a serious, potentially life-
threatening disorder caused by deposition in organs of AA amyloid fibrils, which derive 
from the circulatory acute-phase reactant, serum amyloid A protein (SAA). AA amyloidosis 
secondary to RA is thus one of the intractable conditions found in patients with collagen 
vascular diseases and is an uncommon yet important complication of RA. 
2. Reactive systemic amyloid A (AA) amyloidosis 
2.1 Associated conditions 
Several chronic inflammatory disorders induce reactive systemic AA amyloidosis as one 
of the serious complications. Organ and tissue damage results from the extracellular 
aggregation of proteolytic fragments from SAA as insoluble AA amyloid fibrils. AA 
amyloidosis occurs in association with chronic inflammatory disorders, chronic local or 
systemic microbial infections, and occasionally malignant neoplasias. In Western 
countries, the most frequent predisposing conditions are rheumatic diseases. AA 
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amyloidosis complicates about 6 % in patients with RA, although the reasons why the 
incidence is lower in the United States than in Europe and Japan are not clear. 
Tuberculosis and leprosy are important causes of AA amyloidosis where these infections 
are endemic. Chronic osteomyelitis, bronchiectasis, chronically infected burns, and 
decubitus ulcers as well as the chronic pyelonephritis of paraplegic patients are other 
well-recognized associations. Castleman’s disease, Hodgkin’s lymphoma and renal 
carcinoma, which often cause fever, other systemic symptoms, and a major acute phase 
response, are the malignancies most commonly associated with systemic AA 
amyloidosis.  
 
 
Table 1. Conditions associated with reactive systemic amyloid A amyloidosis. 
Persistent inflammation supported by chronic diseases, such as rheumatic disorders, chronic 
infections, and neoplasias, is associated with persistently increased release of 
proinflammatory cytokines. [Modified from Pepys, M.B. & Hawkins, P.N. (2003). 
Amyloidosis, In: Oxford Textbook of Medicine, Warrell, D.A., Cox, T.M., Firth J.D. & Benz E.J., 
(Eds), pp. 162-173, Oxford University Press, ISBN-10 0192629220, London, UK.] 
2.2 Clinical features 
AA amyloid fibril involves the viscera but may be widely disturbed without causing clinical 
symptoms. The most common presentation is renal, with non-selective proteinuria due to 
glomerular deposition, and nephrotic syndrome may develop before progression to 
endstage renal failure. The second most common is with organ enlargement, such as 
hepatosplenomegaly or thyroid goiter, with or without overt renal abnormality, but in any 
case AA amyloid fibril deposits are almost always wide spread at the time of presentation. 
Involvement of the heart and gastrointestinal (GI) tract is frequent, but rarely causes 
functional impairment. 
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AA amyloidosis may become clinically evident early in the course of associated disease, but 
the incidence increases with duration of the primary condition. For most patients the 
prognosis is closely related to the degree of renal involvement and the efficacy of treatment 
of the underlying inflammatory condition. Availability of chronic haemodialysis (HD) and 
transplantation prevents early death from uremia per se, but AA amyloid fibril deposition in 
extrarenal tissues is responsible for a less favorable prognosis than other causes of endstage 
renal failure. 
3. Pathophysiology of AA amyloidosis secondary to RA 
RA is a representative of collagen vascular diseases, a group of systemic chronic progressive 
inflammatory disorders based on immunological disharmonies. Typically, AA amyloidosis 
will occur in those patients, who have sustained long-standing active disease. Therefore, AA 
amyloidosis may not be suspected during the early course of a potential disease. In rare 
case, however, it may occur within a year of a clinically apparent inflammatory disease. AA 
amyloidosis does not occur in the absence of an acute-phase response or without elevated 
serum SAA levels. Thus, a sustained high concentration of SAA is a prerequisite for AA 
amyloidogenesis (Fig. 1). AA amyloidosis seems to develop in only a minority of patients 
with active, long-standing inflammatory diseases, which indicate that significant disease-
modifying factors may help modulate the occurrence of AA amyloidosis, the rate of AA 
amyloid fibril deposition in tissues, or induction of tissue damage in this form of 
amyloidosis. The persistent inflammation caused by RA is associated with increased release 
of the proinflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF) . 
These cytokines induce a markedly increased synthesis of the acute-phase protein SAA by 
hepatocytes, the concentration of which can be 100 to 1000-fold higher than normal.  
The progressive nature of AA amyloidosis largely reflects the persistent nature of the 
activity of the underlying conditions and, due to fluctuations of disease activity, not all 
patients show evidence of an acute-phase response at the very time of diagnosis. Although it 
is still unknown exactly how the pathophysiological functions of SAA are associated with 
the pathogenesis of AA amyloidosis, there appears a certain subset of patients, who are 
prone to process SAA into AA amyloid fibrils under different factors, such as proteases, 
proteoglycans, serum amyloid P component (SAP).  
Human AA amyloid fibril deposits consist mostly of N-terminal fragments of SAA, which 
points to proteolytic cleavage of the precursor being a key event in pathogenesis. These AA 
amyloid fibril fragments almost exclusively derive from SAA1, which suggests that specific 
amino acid residues may contribute to a misfolding propensity or that differences in the 
catabolism exist. The fate of SAA depends largely on its interactions with cellular and 
extracellular tissue components. Mononuclear phagocytes are involved in SAA catabolism 
through endocytosis and trafficking to lysosomes, where SAA undergoes degradation.  
A role of mononuclear phagocytes in initiating AA amyloid fibril formation was originally 
postulated because of the presence of AA amyloid fibrils in intracellular vesicles and close to 
cell membranes in amyloid-laden tissues. These phenomena were subsequently demonstrated 
in cell culture models. Studies of human monocyte cell lines showed the accumulation of 
newly formed AA amyloid fibrils in intracellular lysosomal compartments, which indicated 
that aberrant processing of SAA is relevant for the pathogenesis of AA amyloidosis. A role of 
monocytes in mediating prion-like transmissibility of AA amyoid fibrils acting as seeds was 
also suggested. Furthermore, SAA binds specifically to the heparan sulfate (HS)-
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glycosaminoglycan complex, a common constituent of all kinds of amyloid deposits that was 
demonstrated to facilitate conformational conversion of a precursor to a -plated sheet 
structure. Also, the SAA-HS interaction promotes AA fibrillogenesis by acting as a scaffold for 
fibril assembly. Both SAA and AA were reportedly biosynthesized by blood or tissue matrix 
metalloproteinases (MMPs) and cathepsin D, and this process may in part result in 
amyloidogenic peptide formation. AA amyloid fibrils would form within lysosomes in 
macrophages because of disturbed SAA processing. As another factor in amyloid metabolism, 
mannose-binding lectin (MBL) is a liver-derived protein involved in lectin-mediated 
complement activation, and lower serum MBL levels are thought to lead to reduced 
macrophage function. MBL-2 polymorphism determines the blood MBL level and is associated 
with the role of mononuclear phagocytes in amyloid metabolism. Susceptibility to AA 
amyloidosis has been linked to mononuclear phagocyte function, and SAA processing by 
monocytes under stimulation with IL-1 or interferon was reportedly disturbed in patients with 
AA amyloidosis, which suggests inflammation-induced abnormalities in monocyte function.  
Although synthesis of AA amyloid fibrils may be closely related to abnormal processing of 
SAA and AA in macrophages, the affinity of AA amyloid fibrils for different organs largely 
accounts for the heterogeneity of such AA amyloid deposits, which still requires explanation. 
In addition, MMPs contribute to proteolytic remodeling of SAA, with production of 
amyloidogenic species. Tissue glycosaminoglycans facilitate formation and local deposition of 
AA amyloid fibrils, along with other amyloidogenic substances, which may be protected from 
clearance by interaction with the pentraxin SAP. The main target organ of deposition is the 
kidney, with resulting significant proteinuria and progression toward renal failure. In cases of 
GI AA amyloidosis, decreased GI motility causes bacterial overgrowth, bile acid 
deconjugation, and consequently diarrhea, steatorrhea, and severe malabsorption.  
 
 
Fig. 1. Pathogenic events involved in amyloid A (AA) amyloidogenesis. 
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Persistent inflammation caused by chronic diseases is associated with a continuous increase 
in proinflammatory cytokines (IL-1: interleukin-1, TNF: tumor necrosis factor , IL-6: 
interleukin-6). These cytokines induce markedly increased synthesis of the acute phase-
phase protein serum amyloid A protein (SAA). Abnormal processing of SAA by 
mononuclear phagocytes is thought to initiate amyloidogenic peptide production and 
formation of amyloid A (AA) amyloid fibrils in lysosomes. Matrix metalloproteinases 
(MMPs) and cathepsin D (Cath D) contribute to proteolytic remodeling of SAA, with 
production of amyloidogenic species. AA fibrils, plus serum amyloid P component (SAP) 
and apolipoprotein E (ApoE), and after interaction with haparan sulfate-
glycosaminoglycans (HS-GAG), deposit in multiple organs. SAA and AA participate in 
inflammation through receptors on inflammatory cells. RAGE: receptor for advanced 
glycation end products; FPRL1: formyl peptide receptor-like 1; TLR2, 4: toll-like receptor 2 
and 4; CLA-1: CD36 and LIMPII analogous-1, human orthologue of the scavenger receptor 
class B type I (SR-BI); GI: gastrointestinal. [From Nakamura, T. (2011). Amyloid A 
amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment. Clinical and 
Experimental Rheumatology, ISSN 0392-856X Accepted on March 8, 2011. (This article is now 
on process of publication.).] 
4. SAA 
SAA is produced primarily in the liver under proinflammatory cytokines stimulation; it is 
also a central acute-phase protein, like C-reactive protein (CRP). SAA complexes with a 
carrier protein, being transported into serum by high-density lipoprotein (HDL) in 
combination with apolipoprotein E, and plays an important role in enterohepatic cholesterol 
circulation. In obese individuals, the frequency of SAA mRNA expression and blood SAA 
level are both significantly high. Thus, the biologically versatile SAA has a significant 
relationship with lipid metabolism.  
Human SAA composes 104 amino acids, and the four SAA-encoding genes are on 
chromosome 11p15.1. SAA contains three subtypes with different primary structures-
SAA1, SAA2 and SAA4-which make up two groups. Those in the first group, SAA1 and 
SAA2, serve as acute-phase proteins. In the second group, SAA4 is expressed 
constitutively in plasma, is synthesized by different organs and tissues, and is not an 
acute-phase protein. Inflammation induces SAA1 and SAA2 genes and their expression 
but not expression of SAA3 (a pseudogene) and SAA4. SAA4 encodes a structural protein 
of HDL. Because of allele polymorphism, SAA1 has three isoforms (SAA1.1, SAA1.3, and 
SAA1.5) and SAA2 has two (SAA2.1 and SAA2.2), and the serum level of SAA is affected 
by SAA1 polymorphism. Expression of the SAA1.5 allele is associated with high blood 
SAA levels, and SAA1.5 has a high affinity for HDL. The primary structures of SAA1 and 
SAA2 have a 93% amino acid homology. SAA4 shows a 50% homology with the other 
SAA acute-phase proteins. Thus, acute-phase SAA has multiple patterns of protein 
polymorphism. 
The normal functions of SAA are not known fully, although modulating effects on 
reverse cholesterol transport and on lipid functions in the microenvironment of 
inflammatory foci have been proposed. Other reports of potent cell regulatory functions 
of isolated denatured delipidated SAA have yet to be confirmed with physiological 
preparations of SAA-rich HDL. Regardless of its physiological role, the behaviour of 
SAA as an exquisitely sensitive acute phase protein with an enormous dynamic range 
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makes it an extremely valuable empirical clinical marker. It can be used to monitor 
objectively the biological disease responses. Furthermore, routine monitoring of SAA 
should be an integral part of the management of all patients with AA amyloidosis or 
disorders predisposing to it, as control of the primary inflammatory process in order to 
reduce SAA production is essential if AA amyloidosis is to be halted, enable d to regress, 
or prevented.  
4.1 SAA1.3 allele and genetic factors related to AA amyloidosis 
Genetic factors seem to be involved in the prevalence and prognosis, and some factors would 
have an influence on the development and length of the latent period in AA amyloidosis 
secondary to RA. The frequency of SAA1 gene polymorphism and that of SAA1 alleles differ 
among races and regions worldwide. Three main SAA1 alleles-SAA1.1, SAA1.3, and SAA1.5-
are defined by two single-nucleotide polymorphisms (SNPs) in exon 3, resulting in two amino 
acid differences at positions 52 and 57, respectively. In Japanese people, the three alleles occur 
at approximately the same rate. The association between AA amyloidosis and the SAA1 
genotype was first observed in Japanese patients with RA, in whom homozygosity for the 
SAA1.3 allele proved to be a risk factor. The SAA1.3/1.3 genotype in Japanese patients with 
RA was associated with a shorter latency period before AA amyloidosis onset and more severe 
AA amyloidosis-related symptoms; it was also a univariate predictor of survival. Thus, the 
SAA1.3 allele was a risk factor for AA amyloidosis, had an association with clinical severity in 
this population, and served as an indicator of poor prognosis. Among Caucasians, AA 
amyloidosis was often observed in SAA1.1 homozygous individuals, and the SAA1.1 allele 
was thought to be a risk factor for AA amyloidosis.  
 
 
 
Fig. 2. Partial genomic structure and location of single nucleotide polymorphism (SNPs) in 
the SAA1 gene. [From Nakamura, T. (2007). Amyloid A amyloidosis secondary to 
rheumatoid arthritis: an uncommon yet important complication. Current Rheumatology 
Reviews, Vol. 3, No. 3, (August 2007), pp. 231-241, ISSN 1573-3971.] 
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With regard to SNPs of the SAA1 gene promoter region, -13T is a high-risk factor for AA 
amyloidosis in Japanese patients with RA, with -13T/T and -13T/C being closely associated 
with AA amyloidosis than is -13C/C. Because SAA1 gene polymorphism affects both blood 
SAA levels and SAA transcriptional activity in hepatocytes, differences in SAA1 proteolysis 
by MMPs indicate a close association between SAA1 gene polymorphism and onset of AA 
amyloidosis. However, the mechanism by which SAA1 gene polymorphism is related to the 
onset of AA amyloidosis and the reason for ethnic differences in disease-susceptible SNPs 
are yet unknown.  
The most extensively studied genetic marker in RA is HLA-DRB1. Several HLA-DRB1 alleles 
share a common amino acid sequence, which is commonly called the shared epitope (SE), in 
the third hypervariable region of the molecule. Recently, it is reported that SE associates 
with not only the disease susceptibility of RA, but also the RA chronicity, severity, and 
extra-articular manifestations, in particular AA amyloidosis in RA patients. It is of particular 
importance that DRB1*04SE has an increased risk of AA amyloidosis in RA and a higher 
prevalence of double *04SE of HLA-DR4 is demonstrated in patients with AA amyloidosis 
secondary to RA.  
The SAA2 gene is located in p-terminus side from the SAA1 gene. Positions of nucleotides 
in the sequence of SAA1 are numbered relative to transcription start site of exon 1. The 
site of SNPs at both 2995 and 3010 underlined, leading to the SAA1 protein 
polymorphism.  
4.2 SAA receptors 
Several SAA receptors have been described, including CD36 and LIMPII analogous-1 
(CLA-1); lipoxin A1 receptor/formyl peptide receptor-like 1 (FPRL1); tanis, a hepatic 
receptor activated by glucose; and toll-like receptor (TLR) 4 and TLR2. SAA reportedly 
activated rheumatoid synovial fibroblasts by binding to receptors for advanced glycation 
end products (RAGE). Also, an HDL receptor, the scavenger receptor class B type I (SR-
BI), is expressed in RA synovial tissue and is apparently involved in SAA-induced 
inflammation in arthritis, including production of SAA-induced reactive oxygen species 
(ROS) and proliferation of fibroblasts. Although RAGE is a receptor for signal 
transduction with biological stimuli, neither SAA nor AA is incorporated into cells via 
this receptor. SAA serves as a chemoattractant for neutrophils, T cells, and monocytes via 
FPRL1 and induces production of CCL2, which is a prototype of the CC chemokine 
subfamily that has the highest chemotactic activity for monocytes. Because cytotoxic 
drugs and cytokine inhibitors affect AA amyloid deposits via their ability to suppress 
SAA production, anticytokine therapies, by inhibiting expression of RAGE, have been 
proposed to reduce interactions between AA amyloid fibrils and RAGE and thereby 
prevent AA-mediated cell toxicity.  
SAA reportedly exerts cytokine-like actions, stimulates fibroblast differentiation, and 
elevates ROS production in neutrophils and fibroblasts. Furthermore, not only does SAA 
induce synthesis of MMP-1 and MMP-3 in synoviocytes and chondrocytes and increase 
production of MMP-9, but it is also involved in innate immunity via TLR4. Additional 
studies must identify specific receptor(s) involved in SAA-induced biological phenomena 
in health and disease.  
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5. Clinical features and diagnosis of AA amyloidosis secondary to RA  
Clinical features of overt AA amyloidosis include long-term psychological distress of RA, 
markedly high disease activity, and significant inflammatory states. Although a high level 
of blood SAA is an important factor associated with AA amyloidosis onset, this factor 
does not always lead to AA amyloidosis in all patients. Several important factors, 
including the genetic one, are believed to modify the onset of AA amyloidosis. The actual 
incidence of AA amyloidosis in RA is still undefined and probably underestimated, in 
that distinguishing clinical and subclinical phase is quite difficult. A cohort study of 
patients with RA showed that fat AA amyloid deposits were not uncommon-16.3%-so 
subclinical AA amyloidosis may indeed be common in RA. Prevalent values of AA 
amyloidosis in RA patients in recent series ranged from 7% to 26%. The prevalence of 
clinical amyloidosis is likely to be lower, however, as it probably reflects differences in RA 
treatments and in genetic backgrounds. 
AA amyloid deposits primarily target the kidneys, liver, and spleen, and AA amyloidosis 
becomes clinically overt mainly when renal damage occurs, manifesting as proteinuria, 
nephrotic syndrome, or impaired renal function. Proteinuria is the clinical sign that most 
often leads to diagnosis of AA amyloidosis in RA patients. Diagnosis must be based on 
histological examination of tissue specimen, such as from upper GI or rectal biopsy. 
Although mucosal biopsy of the upper GI tract to screen for AA amyloid fibril deposition is 
an easy, simple diagnostic method, antiulcer drugs may mask amyloidotic signs and 
symptoms in the GI tract, which may delay diagnosis of AA amyloidosis in RA patients. 
Positive Congo-red staining, susceptibility to oxidation with potassium permanganate, and 
green birefringence by polarization microscopy after Congo-red staining can confirm the 
presence of AA amyloid fibrils, however. 
5.1 Predictive and prognostic factor of SAA1.3 allele genotype 
Whereas there is startling variation in the frequency of AA amyloidosis worldwide, 
differences also exist for AA amyloidosis complicating RA. The reasons, however, for the 
marked geographic differences are still unclear. A closer relationship between SAA1.3 allele 
and AA amyloidosis secondary to RA is known, that is considered to be one of the factors 
responsible for the lower incidence of AA amyloidosis among Western patients with RA. 
Though AA amyloidosis usually develops more than 10 years after the onset of RA, one RA 
patient complicated by severe AA amyloidosis was encountered just one year after the onset 
of RA, who was proven to be an SAA1.3 homozygote. Subsequent statistical analysis of a 
large number of RA patients with AA amyloidosis carrying SAA1.3 allele revealed that the 
risk for association of AA amyloidosis was about 8 times higher for SAA1.3 homozygotes 
than for the control group, and that homozygotes can develop AA amyloidosis very early 
after the onset of RA. It was thus shown that SAA1.3 allele serves not only as a risk factor for 
the association with AA amyloidosis, but also as a poor prognostic factor in Japanese 
patients with AA amyloidosis secondary to RA (Fig.3). The generalization of the importance 
of SAA1.3 allele as both risk and poor prognostic factor may be limited for some reasons; the 
lack of wide-range control studies, the ethnic differences in SAA gene polymorphism, the 
relative small number of patients with AA amyloidosis, and the heterogeneity in RA and 
healthy controls. Although a crude agreement of the significance of SAA1.3 allele in AA 
amyloidosis in Japanese RA patients is recognized, careful and discreet attitude should be 
required when judging the utility in between SAA1.3 allele and AA amyloidosis.  
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Fig. 3. Kaplan-Meier survival curve in RA disease course for RA patients with (continuous 
line) and without (dotted line) SAA1.3/1.3 (p=0.015, log-rank test). [From Nakamura, T., 
Higashi, S., Tomoda, K., Tsukano, M., Baba, S. & Shono, M. (2006). Significance of SAA1.3 
allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. 
Rheumatology (Oxford), Vol. 45, No. 1, (January 2006), pp. 43-49, ISSN 1462-0324.] 
5.2 Clinical diversity and severity 
It is suggested that SAA1.3 allele genotype could be related with the symptomatic diversity 
and severity in patients with AA amyloidosis secondary to RA. Amyloidotic involvement of 
the urinary bladder is very rare but severe, which is often revealed massive macroscopic 
hematuria. Once massive hematuria occurs it would trend to be fatal. Secondary bladder AA 
amyloidosis should be considered as a possible cause of hematuria in patients with long-
standing RA, especially carrying SAA1.3 allele, and as an important prognostic factor of RA. 
5.3 Prevalence 
Though subclinical phase of AA amyloidosis is defined by the formation of AA amyloid 
deposits in tissue without any clinical manifestation, it is very hard to distinguish clinical 
from subclinical phase. Obviously, it is difficult to evaluate the natural history of AA 
amyloid deposition and to know the length of this phase and its final outcome. The 
prevalence of clinical amyloidosis is likely to be lower. Taking the discordance between 
prevalence rates of clinical and subclinical AA amyloidosis into consideration, the wide 
variation in the prevalence of AA amyloidosis secondary to RA is due, in part, to the 
frequency for the marked geographic differences worldwide, possibly including genetic 
factors, and due to the lack of unified statistical studies for AA amyloidosis between races 
and districts. That seems to reach the notion AA amyloidosis would be complicated with RA 
more than so far estimated. 
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5.4 Outcome 
The survival time after the diagnosis of AA amyloidosis secondary to RA seems to be 4-5 
year. These are, of course, dependent on the time at which AA amyloidosis is verified, 
which may differ considerably among patients. This partly explains the great individual 
variation in survival time observed, that leads us the notion that an active diagnostic 
attitude towards AA amyloidosis in patients with RA is advisable. Although the 
relationship among the production of AA precursor protein, the turnover of AA amyloid 
fibrils, and amyloidotic organ function is complex, it has been proved that outcome is 
favorable in AA amyloidosis when SAA concentration is maintained below 10g/ml. The 
clinical risk factors associated with a poor survival included female, older age, a reduced 
serum albumin, and an increased serum creatinine concentration upon diagnosis of AA 
amyloidosis (Fig. 4). Renal involvement has been considered to be the most critical problem 
in patients with AA amyloidosis, and dominates the clinical picture in AA amyloidosis 
 
 
Fig. 4. Kaplan-Meier survival curve after diagnosis of AA amyloidosis for patients with 
serum creatinine >2.5 mg/dl (continuous line) and serum creatinine≦2.5 mg/dl (dotted 
line) (p=0.013, log-rank test). [From Nakamura, T., Higashi, S., Tomoda, K., Tsukano, M., 
Baba, S. & Shono, M. (2006). Significance of SAA1.3 allele genotype in Japanese patients with 
amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford), Vol. 45, No. 1, 
(January 2006), pp. 43-49, ISSN 1462-0324.] 
Amyloidotic cardiac involvement has been revealed to trend to be a poor prognostic factor. 
Heart failure is likely to be directly responsible for death in only a minority of patients, 
however, patients with heart failure may be complicated by multiple organ failures in later 
phase of the RA disease course. It seems to be suggested that dysautonomia plays an 
important role in etiology of heart failure to some extent in patients with AA amyloidosis in 
addition to direct AA amyloid fibril deposits in situ. Although the number of reports 
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published to date concerning AA amyloidosis and autonomic nerve dysfunction in patients 
with RA is extremely rare, taking an importance of cardiovascular symptoms into account of 
dysautonomia, which could induce sudden death in AA amyloidosis secondary to RA, 
autonomic nerve dysfunctions may serve as one of the clinical predictors of poor prognosis 
in RA. Dysautonomia like abnormal gustatory sweating or orthostatic hypotension seems to 
be one of the typical symptoms in endstage of the disease course in RA patients with AA 
amyloidosis. 
5.5 Causes of death 
Infection and renal failure are generally the commonest causes of death in RA patients with 
AA amyloidosis, and they comprised 42.3% and 19.2% of deaths, respectively. A higher risk 
of severe infections is a substantial problem in management of RA with AA amyloidosis. 
Also, the higher causal proportion of renal failure and GI diseases than RA patients without 
AA amyloidosis can be attributable to more AA amyloid fibril deposition in these organs. 
6. Treatment of AA amyloidosis secondary to RA 
The principal aim in treating RA patients with AA amyloidosis is to switch off SAA 
production, by controlling the RA inflammatory process. Anti-inflammatory treatment must 
be empirical but, as in all patients with AA amyloidosis, should be guided by frequent 
assessment of SAA concentrations in view of reported correlations between survival and 
this measure. Estimated survival at 10 years was 90% in AA amyloidosis patients whose 
median SAA concentration was below 10 g/ml and was 40% among those whose median 
SAA exceeded this value, which were statistically significant results. Treatment of AA 
amyloidosis secondary to RA may involve the following strategies.  
6.1 Suppression of SAA production  
The efficacy of corticosteroid treatment on AA amyloidosis secondary to RA is still 
controversial. Corticosteroids are capable of reducing the magnitude of acute phase reaction 
including synthesis of CRP and SAA. In human hepatocyte cultures a stimulating effect of 
corticosteroids was seen on SAA but not on CRP production. Although corticosteroid 
suppresses both CRP and SAA levels in longitudinal studies of patients with RA, the effect 
is somewhat more pronounced for CRP than for SAA. Monitoring of SAA instead of CRP 
levels would be advisable particularly if corticosteroids are being used. It seems reasonable 
to treat patients with AA amyloidosis secondary to RA using cytostatic drugs either alone or 
in combination with prednisolone. As the effect of cytostatics may take weeks or months to 
appear, it is recommended to give steroids in addition in order to ensure an immediate 
reduction of the acute phase response and in particular the synthesis of SAA.  
Traditional management of AA amyloidosis has been to target RA disease process behind 
the inflammation. Although there is no evidence that disease-modifying anti-rheumatic 
drugs (DMARDs) have a specific effect on amyloidogenesis and AA amyloidosis in RA, 
there have been encouraging reports evaluating alkylating agents as beneficial in clinical 
trials in RA patients with AA amyloidosis. It is suggested that the use of 
immunosuppressive agents can improve prognosis, and cyclophosphamide (CYC) has been 
proved to be superior to methotrexate (MTX) in treatment with RA patients with AA 
amyloidosis (Fig.5). The possibility that CYC would be more effective predominantly in 
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patients with SAA1.3/1.3 homozygosity than heterozygosity, suggesting SAA1.3/1.3 
homozygosity as a CYC treatment-susceptible factor. 
 
 
Fig. 5. Differences between CYC and MTX treatments for RA patients with AA amyloidosis. 
The deducted value (placed in figures) was calculated by subtracting the starting value of 
CRP and/or serum creatinine from the endpoint value in each treatment. [From Nakamura, 
T., Higashi, S., Tomoda, K., Tsukano, M., Baba, S. & Shono, M. (2006). Significance of SAA1.3 
allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. 
Rheumatology (Oxford), Vol. 45, No. 1, (January 2006), pp. 43-49, ISSN 1462-0324.] 
For AA amyloidosis in patients with RA, treatment has centered on using cytotoxic agents 
and biologics. Although case reports and studies of small series of patients showed that 
these agents can reverse nephrotic syndrome and even lead to complete resolution of 
proteinuria, anticytokine agents have recently been proposed as therapeutic options 
(Table 2). Anti-proinflammatory cytokine therapy is expected to show efficacy against 
systemic inflammation and against local inflammation mediated by macrophage 
differentiation or activation in glomeruli, such as in renal AA amyloidosis secondary to 
RA. The strategy of these treatments focuses on tight control of underlying RA disease 
activity. Requirements include diagnosis of RA as early as possible and treatment with 
DMARDs, including MTX as the anchor drug. Achieving low disease activity via 
DMARDs early in the disease course has a strong positive outcome on disease 
progression. However, although MTX is the most common and effective drug for RA, 
management of patients with AA amyloidosis secondary to RA and renal involvement is 
too complex to limit the discussion to MTX.  
In RA treatment, tight control of RA is emphasized to obtain clinical remission or lower 
disease activity; this control is possible through periodic evaluations of RA disease 
activity and aggressive pursuit of other more effective treatments. Together with this 
strategy, the genetic predisposition allele SAA1.3, which is a known risk factor for AA 
amyloidosis in Japanese RA patients, should be evaluated when treating both RA and AA 
amyloidosis.  
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Table 2. Selected references to biologics for treatment of AA amyloidosis secondary to RA. 
[Modified from Nakamura, T. (2011). Amyloid A amyloidosis secondary to rheumatoid 
arthritis: pathophysiology and treatment. Clinical and Experimental Rheumatology, ISSN 0392-
856X Accepted on March 8, 2011 (This article is now on process of publication.). ] 
Etanercept and infliximab, both TNFantagonists, can reduce serum SAA levels in RA 
patients with AA amyloidosis, which improves rheumatoid inflammation, reduces swollen 
and tender joint counts, lowers or normalizes proteinuria, and ameliorates renal function. 
Despite the small number of series of patients with AA amyloidosis secondary to RA who 
had etanercept treatment, this drug did benefit both RA inflammation and AA amyloidosis, 
as measured via the surrogate markers DAS28-ESR, CRP, SAA, and proteinuria, in SAA1.3 
allele-carrying RA patients. Also, serum creatinine levels significantly improved in patients 
with mild RA disease and renal dysfunction. This result suggests that the earlier the 
intervention with biologics, the better the outcome for patients. Etanercept alone may 
therefore be efficacious, without MTX.  
Tocilizumab, an IL-6 receptor antagonist, also demonstrates excellent suppression of SAA 
levels and may have potential as a therapeutic agent for AA amyloidosis. Circulating SAA 
normally reflects changes in CRP, and levels of both acute-phase reactants usually 
increase simultaneously, but some differences can occur. SAA and CRP seem to be partly 
influenced by different cytokines. IL-6-blocking therapy has shown promise in 
normalizing serum SAA levels in RA patients. Moreover, blocking IL-6 alone, but not IL-1 
or TNF, completely prevented SAA mRNA expression in human hepatocytes during 
triple cytokine stimulation. For signal transduction, IL-6 binds to membrane-bound IL-6 
receptor gp80, and then the IL-6-gp80 dimer interacts with gp130. Formation of gp130-
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containing complexes leads to activation of Janus kinases (JAKs), which stimulates signal 
transducers and activators of transcription (STATs). Certain evidence suggests that STAT3 
is the key transcription factor responsible for IL-6 activation of SAA gene transcription. 
Therefore, the function of JAK inhibition in the IL-6 signaling pathway will be one target 
of RA treatments. Suppressing IL-6-mediated proinflammatory signaling pathways via 
JAK inhibitors may be a novel anti-inflammatory therapeutic strategy for RA and AA 
amyloidosis. Another agent, tacrolimus, may inhibit T-cell function in pathogenesis of AA 
amyloidosis. 
6.2 Inhibition of AA amyloid fibril deposits 
Eprodisate, a small sulfonated molecule with structural similarity to heparan sulfate, which 
can cause regression of amyloidosis by destabilizing the glycoasaminoglycan backbone of 
amyloid deposits, delayed progression of renal disease associated with AA amyloidosis. In a 
trial for AA amyloidosis, eprodisate had a beneficial effect on the rate of deterioration of 
renal function but no effect on urinary protein excretion . That eprodisate did not affect SAA 
levels and preserved kidney function but had no effect on proteinuria raises the interesting 
possibility that it is the precursors of mature amyloid fibrils are responsible for proteinuria 
in amyloidosis.  
6.3 Removal of deposited AA amyloid fibrils 
The normal plasma protein SAP binds to all types of amyloid fibrils and contributes to 
amyloidosis pathogenesis. A pyrrolidine carboxylic acid derivative, which is a competitive 
inhibitor of SAP binding to amyloid fibrils, can intervene in this process and affect SAP 
levels. This compound cross-linked and dimerized SAP molecules, which led to extremely 
rapid clearance by the liver, and thus produced marked depletion of circulating human 
SAP. This drug action thus removed SAP from human amyloid deposits in tissues and may 
have a favorable effect on amyloidosis. 
Another compound, dimethyl sulfoxide (DMSO), is a hydrogen-bond disrupter, cell-
differentiating agent, hydroxyl radical scavenger, cryoprotectant, and solubilizing agent that 
is used as a compound for preparation of samples for electron microscopy, as an 
intracellular low-density lipoprotein-derived cholesterol-mobilizing antidote to 
extravasation of vesicant anticancer agents, and as a topical analgesic. A notable DMSO side 
effect is garlic-like breath odor and taste in the mouth because of pulmonary excretion of a 
small amount of DMSO as dimethyl sulfide. Oral DMSO was effective against AA 
amyloidosis, especially GI involvement and early renal dysfunction, but using it would not 
likely be feasible in current clinical practice. 
6.4 Treatment of organ failure 
The predominant feature of AA amyloidosis is proteinuria with or without renal failure. If 
conservative treatment of renal failure is not sufficient, renal replacement therapy including 
renal transplantation, continuous ambulatory peritoneal dialysis, or HD should be 
considered. Even in RA patients with AA amyloidosis who undergo HD, anti-TNF 
blockers can demonstrate efficacy. HD reportedly had no effect on plasma etanercept 
concentration, and etanercept pharmacokinetics in patients undergoing HD for chronic 
renal failure were similar to those with normal renal function. Administration of etanercept 
to HD patients would therefore appear reasonable.  
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For RA patients complaining severe diarrhea due to AA amyloidosis, corticosteroid, codeine 
phosphate, and lactate bacteriae are useful. In remarkable protein losing enteropathy with 
intractable diarrhea due to AA amyloidosis, a successful treatment combined with 
somatostatin analogue octreotide and corticosteroid has been reported. 
7. Biological diversity and significance of SAA 
The life expectancy of patients with RA has been estimated to be 1.2 to 1.7 times worse than 
that of the general population. Complications involving AA amyloidosis may further reduce 
life expectancy in such patients. Treatment-related clinical remission in RA may lead to 
structural and functional remissions, which will result in a better quality of life. SAA has 
biologically diverse and significant roles in health and disease (Fig. 6). Thus, SAA may 
modify progression of disease-either AA amyloidosis (high-grade inflammation) or 
metabolic syndrome (low-grade inflammation)-via its biological actions. Alleviated 
inflammation and improved nutritional metabolism would lead to suppression of 
cardiovascular events and would reduce the incidence of AA amyloidosis in RA. 
Elucidation of the biological diversity and significance of SAA should enhance 
understanding of the pathophysiology of AA amyloidosis secondary to RA. 
 
 
Fig. 6. Biological versatility of serum amyloid A protein (SAA). 
SAA plays important roles in both high-grade inflammation and low-grade inflammation. It 
acts, as cytokines do, via autocrine, endocrine, and paracrine mechanisms. As a precursor 
protein of amyloid A (AA) fibrils, SAA induces AA amyloidosis. SAA also affects metabolic 
syndrome via various modes of action. These humoral and cellular inflammatory events 
interact, with SAA being a key player. RAGE: receptor for advanced glycation end products; 
FPRL1: formyl peptide receptor-like 1; TLR2, 4: toll-like receptor 2 and 4; CLA-1: CD36 and 
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LIMPII analogous-1, human orthologue of the scavenger receptor class B type I (SR-BI); 
AGEs: advanced glycation end products. [From Nakamura, T. (2011). Amyloid A 
amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment. Clinical and 
Experimental Rheumatology, ISSN 0392-856X Accepted on March 8, 2011 (This article is now 
on process of publication.).] 
8. Issues that require further perspective 
Important issues of future interest that are related to AA amyloidosis secondary to RA include 
the following: i) tight control of inflammation occurring with underlying RA; ii) factors 
associated with the risk of AA amyloidosis, such as SAA1.3 allele, which indicates a genetic 
predisposition to the disease; and iii) screening tools for AA amyloidosis for use even during 
the subclinical phase. The mechanisms of AA amyloid fibril formation are complicated 
pathways involving multiple factors, as Figure 1 shows, and elucidation of mechanisms on 
both deposition and turnover of AA amyloid fibrils should allow development of novel 
therapeutic options. Reducing the supply of amyloidogenic precursors is usually associated 
with reabsorption of AA amyloid deposits and perhaps recovery of target organ function. 
Because AA amyloid fibril shows heterogeneity in organ deposition, clarification of the affinity 
of AA amyloid fibrils to various organs is needed. Addressing the involvement of various 
organs and systems- renal, GI, cardiac, thyroid, and autonomic nervous-may permit 
development of therapeutic countermeasures against complications.  
9. Conclusion 
Although significant advances have been made in understanding of the pathology, 
pathogenesis, and clinical treatment of AA amyloidosis secondary to RA, the disease is still 
an important complication that warrants investigation. The SAA1.3 allele serves not only as 
a risk factor for AA amyloidosis but also as a factor related to poor prognosis and shortened 
survival of Japanese patients with RA, and understanding both disorders would benefit 
from investigation of the SAA1.3 allele. AA amyloidosis secondary to RA is now clearly 
influenced by many variables, and clinical pictures differ among patients. The pathological 
process in RA patients with AA amyloidosis seems to be more complicated and subtle than 
previously realized. Clarification of the formation and degeneration or turnover of AA 
amyloid fibrils and elucidation of the biological contributions of SAA in health and disease 
are indispensable prerequisites to the management of AA amyloidosis secondary to RA.  
The introduction of biological therapies targeting specific inflammatory mediators 
revolutionized the treatment of RA. Targeting key components of the immune system 
allows efficient suppression of the pathologic inflammatory cascade that gives rise to RA 
symptoms and subsequent joint destruction. Reactive AA amyloidosis is one of the most 
severe complications of RA, and is a serious, potentially life-threatening disorder caused by 
deposition in multiple organs of AA amyloid fibrils. The AA amyloid fibrils are derived 
from the circulatory acute-phase reactant, SAA, and likely subject to control. With newly 
developed biologics, AA amyloidosis secondary to RA seems to become a treatable and 
even controllable disorder. The pathophysiological understanding and clinical factors 
including the genetic predisposition require that rheumatologists need to take these into 
account when diagnosing and treating patients with AA amyloidosis secondary to RA. 
Based on previous works as to AA amyloidosis secondary to RA, the critical overview in 
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terms of AA amyloidosis is discussed with special reference to therapeutic importance of 
biologic agents.  
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